Effect of Melanin Biosynthesis Inhibition on the Antifungal Susceptibility of Chromoblastomycosis Agents

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2021 May 11

PMID 33972246

Citations 7

Authors

Daiane Heidrich

Danielle Machado Pagani

Alessandra Koehler

Karine de Oliveira Alves

Maria Lucia Scroferneker

Affiliations

Soon will be listed here.

Abstract

Chromoblastomycosis (CBM) is a chronic subcutaneous infection caused by genera of melanized fungi: , , , , and . Melanin is a virulence factor known to influence antifungal susceptibility. A specific inhibitor of melanin biosynthesis is tricyclazole. The aim of this study was to evaluate the effect of melanin inhibition on antifungal susceptibility of chromoblastomycosis agents and describe the susceptibility profiles of some unusual CBM agents. Seventy-six clinical isolates, representing 13 species of the five main genera of CBM agents, were studied. The antifungal susceptibility testing was performed according to the M38-A2 protocol of CLSI (, 3rd ed., , 2017). In the melanin inhibition test, 16 mg/liter of tricyclazole was added to the medium used in the inoculum preparation and the susceptibility assay. CBM agents were less susceptible to amphotericin B than azoles and terbinafine. The unusual species showed similar susceptibility profiles to those of other species of the same genera. With tricyclazole exposure, MICs of terbinafine, posaconazole, and itraconazole for spp. significantly decreased ( < 0.05). For spp., this reduction was significant for posaconazole and itraconazole. For the other genera, there was a reduction in MICs of terbinafine and itraconazole; however, the statistical tests were not significant. Melanin inhibition can increase the antifungal susceptibility of most CBM agents to itraconazole and terbinafine, the main drugs used in the disease treatment. This increased susceptibility may open up new possibilities for therapy in refractory cases of CBM and/or cases caused by resistant fungal strains. Further studies are needed to confirm the same results .

Citing Articles

Dematiaceous Molds.

Li L, Yoon H Infect Dis Clin North Am. 2024; 39(1):75-92.

PMID: 39701900 PMC: 11786988. DOI: 10.1016/j.idc.2024.11.006.

Role of Posaconazole Drug in the Treatment of Invasive Fungal Disease: A Review.

Singh S, Pancholi S Infect Disord Drug Targets. 2024; 25(2):e18715265307531.

PMID: 39313878 DOI: 10.2174/0118715265307531240801091445.

Development of PCR-Multiplex Assays for Identification of the Herpotrichiellaceae Family and Agents Causing Chromoblastomycosis.

Sousa G, De Oliveira R, Souza A, Monteiro R, Santo E, Franco Filho L J Fungi (Basel). 2024; 10(8).

PMID: 39194874 PMC: 11355602. DOI: 10.3390/jof10080548.

Silver(I) 1,10-Phenanthroline Complexes Are Active against Viability and Negatively Modulate Its Potential Virulence Attributes.

Sousa I, Vieira T, Menna-Barreto R, Guimaraes A, McCarron P, McCann M J Fungi (Basel). 2023; 9(3).

PMID: 36983524 PMC: 10057124. DOI: 10.3390/jof9030356.

Analysis of the synergistic antifungal activity of everolimus and antifungal drugs against dematiaceous fungi.

An L, Jia G, Tan J, Yang L, Wang Y, Li L Front Cell Infect Microbiol. 2023; 13:1131416.

PMID: 36909734 PMC: 9996166. DOI: 10.3389/fcimb.2023.1131416.

References

Li X, Guo B, Cai W, Zhang J, Huang H, Zhan P . The role of melanin pathways in extremotolerance and virulence of Fonsecaea revealed by de novo assembly transcriptomics using illumina paired-end sequencing. Stud Mycol. 2016; 83:1-18. PMC: 4969264. DOI: 10.1016/j.simyco.2016.02.001. View

Daboit T, Magagnin C, Heidrich D, Antochevis L, Vigolo S, Meirelles L . In vitro susceptibility of chromoblastomycosis agents to five antifungal drugs and to the combination of terbinafine and amphotericin B. Mycoses. 2013; 57(2):116-20. DOI: 10.1111/myc.12111. View

Heidrich D, Koehler A, Ramirez-Castrillon M, Pagani D, Ferrao M, Scroferneker M . Rapid classification of chromoblastomycosis agents genera by infrared spectroscopy and chemometrics supervised by sequencing of rDNA regions. Spectrochim Acta A Mol Biomol Spectrosc. 2021; 254:119647. DOI: 10.1016/j.saa.2021.119647. View

Kogej T, Wheeler M, Rizner T, Gunde-Cimerman N . Evidence for 1,8-dihydroxynaphthalene melanin in three halophilic black yeasts grown under saline and non-saline conditions. FEMS Microbiol Lett. 2004; 232(2):203-9. DOI: 10.1016/S0378-1097(04)00073-4. View

Cunha M, Franzen A, Seabra S, Herbst M, Vugman N, Borba L . Melanin in Fonsecaea pedrosoi: a trap for oxidative radicals. BMC Microbiol. 2010; 10:80. PMC: 2845570. DOI: 10.1186/1471-2180-10-80. View

van de Sande W, de Kat J, Coppens J, Ahmed A, Fahal A, Verbrugh H . Melanin biosynthesis in Madurella mycetomatis and its effect on susceptibility to itraconazole and ketoconazole. Microbes Infect. 2007; 9(9):1114-23. DOI: 10.1016/j.micinf.2007.05.015. View

Najafzadeh M, Badali H, Illnait-Zaragozi M, de Hoog G, Meis J . In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp. Antimicrob Agents Chemother. 2010; 54(4):1636-8. PMC: 2849378. DOI: 10.1128/AAC.01655-09. View

Heidrich D, Corbellini V, Mendes S, Fernandes E, Lazzarotto L, Ribeiro A . Melanin: Quantification and protection against oxidative stress in chromoblastomycosis agents. Med Mycol. 2018; 57(2):260-263. DOI: 10.1093/mmy/myy013. View

Franzen A, Cunha M, Batista E, Seabra S, De Souza W, Rozental S . Effects of tricyclazole (5-methyl-1,2,4-triazol[3,4] benzothiazole), a specific DHN-melanin inhibitor, on the morphology of Fonsecaea pedrosoi conidia and sclerotic cells. Microsc Res Tech. 2006; 69(9):729-37. DOI: 10.1002/jemt.20344. View

10.

Badali H, Bonifaz A, Barron-Tapia T, Vazquez-Gonzalez D, Estrada-Aguilar L, Oliveira N . Rhinocladiella aquaspersa, proven agent of verrucous skin infection and a novel type of chromoblastomycosis. Med Mycol. 2010; 48(5):696-703. DOI: 10.3109/13693780903471073. View

11.

Pinto L, Granja L, Alviano D, Silva M, Alviano C, Ejzemberg R . Activation of the human complement system by pigmented and hypopigmented mycelia of the fungus Fonsecaea pedrosoi. Mycoses. 2011; 54(5):e474-80. DOI: 10.1111/j.1439-0507.2010.01956.x. View

12.

Gomes R, A Vicente V, de Azevedo C, Salgado C, da Silva M, Queiroz-Telles F . Molecular Epidemiology of Agents of Human Chromoblastomycosis in Brazil with the Description of Two Novel Species. PLoS Negl Trop Dis. 2016; 10(11):e0005102. PMC: 5125572. DOI: 10.1371/journal.pntd.0005102. View

13.

Queiroz-Telles F, de Hoog S, Santos D, Salgado C, Vicente V, Bonifaz A . Chromoblastomycosis. Clin Microbiol Rev. 2016; 30(1):233-276. PMC: 5217794. DOI: 10.1128/CMR.00032-16. View

14.

Sun J, Zhang J, Najafzadeh M, Badali H, Li X, Xi L . Melanization of a meristematic mutant of Fonsecaea monophora increases tolerance to stress factors while no effects on antifungal susceptibility. Mycopathologia. 2011; 172(5):373-80. DOI: 10.1007/s11046-011-9439-1. View

15.

de Andrade T, de Almeida A, Basano S, Takagi E, Szeszs M, Melhem M . Chromoblastomycosis in the Amazon region, Brazil, caused by Fonsecaea pedrosoi, Fonsecaea nubica, and Rhinocladiella similis: Clinicopathology, susceptibility, and molecular identification. Med Mycol. 2019; 58(2):172-180. DOI: 10.1093/mmy/myz034. View

16.

Nosanchuk J, Casadevall A . The contribution of melanin to microbial pathogenesis. Cell Microbiol. 2003; 5(4):203-23. DOI: 10.1046/j.1462-5814.2003.00268.x. View

17.

van Duin D, Casadevall A, Nosanchuk J . Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin. Antimicrob Agents Chemother. 2002; 46(11):3394-400. PMC: 128748. DOI: 10.1128/AAC.46.11.3394-3400.2002. View

18.

Coelho R, Brito-Santos F, Figueiredo-Carvalho M, Silva J, Gutierrez-Galhardo M, do Valle A . Molecular identification and antifungal susceptibility profiles of clinical strains of Fonsecaea spp. isolated from patients with chromoblastomycosis in Rio de Janeiro, Brazil. PLoS Negl Trop Dis. 2018; 12(7):e0006675. PMC: 6080783. DOI: 10.1371/journal.pntd.0006675. View

19.

Nosanchuk J, Casadevall A . Impact of melanin on microbial virulence and clinical resistance to antimicrobial compounds. Antimicrob Agents Chemother. 2006; 50(11):3519-28. PMC: 1635213. DOI: 10.1128/AAC.00545-06. View

20.

Bonifaz A, Paredes-Solis V, Saul A . Treating chromoblastomycosis with systemic antifungals. Expert Opin Pharmacother. 2004; 5(2):247-54. DOI: 10.1517/14656566.5.2.247. View